Bone Marrow Stem Cell Therapy for Limb Ischemia Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods using autologous bone marrow to stimulate angiogenesis for ischemic diseases are limited by reduced efficacy with aging and comorbidities, necessitating enhanced agents to augment the ability of bone marrow cells to promote collateral circulation.
Innovation Solution
Administration of bone marrow mononuclear cells in a modified microenvironment, combined with antioxidants and NF-kappa B inhibitors, to enhance regenerative activity and angiogenesis in patients with ischemic diseases such as heart failure, stroke, and limb ischemia, using methods like intra-muscular gene delivery via viral vectors or mRNA liposomal delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone marrow is used to stimulate angiogenesis, then collateral circulation is promoted, but efficacy is reduced with aging and comorbidities
Solution Approach 1:
The patent introduces a modified microenvironment as an intermediary that mediates between the bone marrow cells and the ischemic tissue. This microenvironment contains growth factors, cytokines, and other bioactive molecules that enhance the therapeutic effect of bone marrow cells, particularly in aged or comorbid patients whose cells would otherwise have reduced efficacy.
Solution Approach 2:
The patent modifies the microenvironment by changing its chemical and biological parameters - adding specific growth factors, adjusting pH, modifying oxygen tension, or introducing anti-inflammatory agents. These parameter changes create optimal conditions for bone marrow cell function and angiogenesis, compensating for age-related declines in cell quality.
2Productivity
If bone marrow mononuclear cells are administered in modified microenvironment, then angiogenesis and tissue regeneration are enhanced, but treatment complexity increases
Solution Approach 1:
The patent combines multiple therapeutic agents and modifications into a single integrated microenvironment formulation that is co-administered with bone marrow cells. This merging of growth factors, cytokines, and other modifiers into one composite treatment reduces the need for separate administration steps and simplifies the overall protocol while maintaining enhanced therapeutic effects.
3Object-affected harmful factors
If antioxidants and NF-kappa B inhibitors are added to modify microenvironment, then oxidative stress is reduced and regenerative activity is enhanced, but cost and treatment complexity increase
Solution Approach 1:
The patent converts the harmful oxidative stress environment into a beneficial therapeutic opportunity by introducing antioxidants that neutralize reactive oxygen species. The modified microenvironment transforms the damaging oxidizing conditions into a protected reducing environment that promotes stem cell survival and differentiation, effectively using the presence of oxidative stress as a target for therapeutic intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases angiogenesis and tissue regeneration, improving blood flow and reducing oxidative stress, thereby enhancing treatment outcomes for ischemic diseases by augmenting the efficacy of bone marrow cells.
Implementation Method 1
reducing oxidative stress
Implementation Method 2
intra-muscular gene delivery via viral vectors
Implementation Method 3
mRNA liposomal delivery
Implementation Method 4
stimulate angiogenesis
Data Source
AI summary
Methods and compositions are provided to treat limb ischemia such as Beurger's Disease through the use of bone marrow stem cells that are administered prior to, concurrently with, and subsequently to administration of agents that modify the microenvironment of the ischemic limb(s). In one embodiment, said agents are antioxidants, more specifically antioxidants capable of diffusing across ischemic areas and preserving regenerative activity of administered stem cells. In another embodiment, the invention provides hormonal modifications to overcome deficiencies associated with ischemia predisposing pathologies.